Gynecologic Oncology Group
Trial Pipeline
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
NCT01000259
Abemaciclib and Letrozole to Treat Endometrial Cancer
NCT04393285
Ribociclib and Letrozole Treatment in Ovarian Cancer
NCT03673124
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01225887
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01267253
Prognostic Biomarkers in Patients With Endometrial Cancer
NCT01208467
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
NCT01139957
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
NCT01198171
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT01164735
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
NCT01344837
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00939809
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00309959
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
NCT00081263
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
NCT00031629
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
NCT00104910
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix
NCT00087113
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
NCT00064025
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
NCT00101127
Vaginal Changes and Sexual Function in Patients With Cervical Cancer
NCT00053261
EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer
NCT00049231
Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
NCT00005031
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
NCT00005026
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
NCT00003325
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
NCT00003377
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003967
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
NCT00003644
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer
NCT00003384
Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix
NCT00003078
Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer
NCT00002536
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002717
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus
NCT00002546
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
NCT00002538
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer
NCT00002493
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 13 |
| Phase 3 | 7 |
Therapeutic Areas
What the Pipeline for Gynecologic Oncology Group Shows
According to the ClinicalTrials.gov registry, Gynecologic Oncology Group is linked to 61 US clinical trials across every stage of research activity. Of those, 29 studies are currently recruiting — about 48% of the sponsor's indexed portfolio — and 30 are already marked complete, representing roughly 49% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Gynecologic Oncology Group reports 7 late-stage studies (Phase 3 and Phase 4 combined) and 17 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Gynecologic Oncology Group is Cervical Cancer with 6 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.